High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance

It has been postulated that monitoring measurable residual disease (MRD) could be used as a surrogate marker of progression-free survival (PFS) in chronic lymphocytic leukemia (CLL) patients after treatment with immunochemotherapy regimens. In this study, we analyzed the outcome of 84 patients at 3...

Full description

Bibliographic Details

Published in:	Haematologica (Roma) 2019-11, Vol.104 (11), p.2249-2257
Main Authors:	García-Marco, José A., Jiménez, Javier López, Recasens, Valle, Zarzoso, Miguel Fernández, González-Barca, Eva, De Marcos, Nieves Somolinos, Ramírez, M. Jose, Parraga, Francisco Javier Peñalver, Yañez, Lucrecia, De La Serna Torroba, Javier, Malo, Maria Dolores Garcia, Ariznavarreta, Guillermo Deben, Persona, Ernesto Perez, Guinaldo, M. Angeles Ruiz, De Paz Arias, Raquel, Llanos, Elena Bañas, Jarque, Isidro, Valle, M. del Carmen Fernandez, Tatay, Ana Carral, De Oteyza, Jaime Perez, Martin, Eva Maria Donato, Fernández, Inmaculada Perez, Martinez, Rafael Martinez, Costa, M. Angeles Andreu, Champ, Diana, Suarez, Julio García, Díaz, Marcos González, Ferrer, Secundino, Carbonell, Félix, García-Vela, José A.
Format:	Article
Language:	English
Citations:	Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!